Effect of Rapid Clinic Follow-Up After Hospital Discharge on 30- Day Heart Failure Readmission Lee Arcement, MD, MPH Dragana Lovre, MD.

Slides:

Advertisements

Similar presentations

© 2010, American Heart Association. All rights reserved. Evolving Patterns of Use and Appropriateness of Aldosterone Antagonists in Heart Failure Nancy.

Advertisements

Bruce Siegel MD, MPH President & CEO January Americas Safety Net: Setting the Bar for the Nation.

Mental Health Division. Big Aim Decrease our inpatient hospital readmission rate Small Aim Increase access to outpatient mental health services through.

For the Healthcare Provider

Bill Stockdale, MBA, Celeste Beck, MPH, Lisa Hulbert, PharmD, Wu Xu, PhD Utah Department of Health Comparison with other methods of analysis: 1) Assessing.

Hernandez et al. JAMA, May 5, 2010 – Vol. 303, No. 17 Relationship Between Early Physician Follow-up and 30-day Readmission Among Medicare Beneficiaries.

Disclosure I, Michael Kaiser, MD, have no relationships with commercial interests to disclose. A commercial interest is any entity producing, marketing,

Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly Findings From the Get With the Guidelines Quality-

“Influence of age on the management of heart failure: Findings from Get With the Guidelines–Heart Failure (GWTG-HF)” Daniel E. Forman, MD; Christopher.

2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research.

RHP 14 Learning Collaborative July 18, DSRIP Project Overview  Key project areas at Odessa Regional Medical Center Speech Pathology Diabetes Education.

2 AMERIGROUP Community Care Entered Maryland market in 1999 Largest MCO in Maryland Serving over 143,000 members in Baltimore City and 20 counties in.

Clinical experience with ezetimibe/simvastatin in a Mediterranean population The SETTLE Study I. Migdalis a, A. Efthimiadis b, St. Pappas c, D. Alexopoulos.

Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.

Address Readmission Rate Robust inpatient management but need for streamlined community navigation HF patients have been using the ED as primary care.

Reduction Of Hospital Readmissions Hany Salama, MD Diplomat ABIM IM Hospice and Palliative Care Sleep Medicine.

Designing Screening Protocols for Diabetes and Pre-diabetes Ron Horswell, PhD (PBRC) Gang Hu, MD PhD (PBRC) Study group: Jolene Johnson, MD (LSU HSC) Will.

D-1 Pravastatin-Aspirin Combination The Medical Need Thomas A. Pearson, M.D., Ph.D. Albert D. Kaiser Professor of Community & Preventive Medicine University.

Do Heart Failure Disease Management Programs Make Financial Sense Under a Bundled Payment System? Zubin J. Eapen, Shelby D. Reed, Lesley H. Curtis, Adrian.

Hospital Story Donna Collins, RN,MS/ CPHQ, Quality Manager, Weeks Medical Center, NH.

IMPACT OF DISPARITIES IN CARDIOVASCULAR CARE ON AFRICAN AMERICAN DEATHS Kevin Fiscella, MD, MPH University of Rochester School of Medicine & Dentistry.

Lee Arcement, MD, MPH. Donabedian’s Quality Triangle-It’s Relevance to Process Improvement -Avedis Donabedian, MD, MPH ( )

Internet-based Telemedicine for Cardiovascular Disease Management Alfred A. Bove, MD, PhD Cardiology Section Temple University Medical Center.

The Affordable Care Act is Transforming Health Care in our Community: The Washington Heights-Inwood Regional Health Collaborative 18th Annual NHMA Conference.

Treatment and Risk in Heart Failure: Gaps in Evidence or Quality? Pamela N. Peterson, MD MSPH; John S. Rumsfeld, MD PhD; Li Liang PhD; Adrian F. Hernandez,

Update of 2013 ACCF/AHA Guidelines for STEMI Junbo Ge MD,FACC,FESC,FSCAI Zhongshan Hospital, Fudan University.

RIGHT CARE INITIATIVE TEAM BASED CARE: A LOCAL EXAMPLE 12/10/12 Phillip Raimondi MD Bridget Levich MSN, CDE University of California Davis Medical Center.

From Knowledge to Practice Translation A Multidisciplinary Intervention to Reduce 30 day Heart Failure Readmissions.

Quality Improvement and Care Transitions in a Medical Home Maryland Learning Collaborative May 21, 2014 Stephanie Garrity, M.S., Cecil County Health Officer.

Heart failure and comorbidities

CHF Team Approach Peter Carson, MD Jacqueline Gannuscio, MSN, ACNP RN Washington DC.

Performance assessment A performance assessment framework is a collation of statistics across a district or within a hospital and is far removed from.

Heart Failure Audit Dr Jenny Welstand Lead Nurse Heart Failure Service Wrexham Maelor Hospital Acknowledgements: North Wales Cardiac Network Dr Richard.

The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.

Reasons for Incomplete Follow Up for HPV Vaccination in Females Attending an Urban Public Immunization Clinic Fiona G. Kouyoumdjian, 1 MD, MPH, CCFP, Anne.

Evaluation of CT Coronary Angiography (CTCA) and Cardiac Magnetic Resonance (CMR) in patients presenting with Acute Chest Pain (ACP) at A&E Background.

Transitions of Care Progress Report

CTC Clinical Strategy and Cost Committee

Suicide Mortality Following VA Irregular Discharges:

Safi U. Khan MD; John Pamula MD

By: Marie-Josée Pagé, DO

EMPHASIS-HF Extended Follow-up

Hospitalizations and Healthcare Costs Need for Reduction in Hospitalizations of Patients With HF

Using the SafeMed model for transitions of care approach

Defining Best Practice:

Heart Failure and Hospital Readmissions

Heart Rate, HF Admissions, and Readmissions

Discharge instructions

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Statins and the Elderly Patient

Using the SafeMed model for transitions of care approach

Aim and Key Driver Diagram

Heart Failure Prevention: Mission Impossible?

Preventing Heart Failure Readmission and Progression

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

Does the implementation of electronic treatment protocols improve adherence to empirical antimicrobial guidelines in the treatment of infective exacerbations.

M. Bradley Drummond, MD MHS Associate Professor, Pulmonary Medicine

Comparing Options for Management:PAtient-centered REsults for Uterine Fibroids Evan R. Myers, MD, MPH Department of Obstetrics & Gynecology and Duke Clinical.

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

New Strategies to Reduce HF Readmissions

Global Registry of Acute Coronary Events: GRACE

Optum’s Role in Mycare Ohio

Program Goals Background: Anticoagulation in Patients With VTE.

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

HF-Related Hospitalization and Readmissions

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Module 5 Part 1 Understanding Baseline Data

Dominique Hansen, PhD, FESC

Many post-MI patients are not receiving optimal therapy

Presentation transcript:

Effect of Rapid Clinic Follow-Up After Hospital Discharge on 30- Day Heart Failure Readmission Lee Arcement, MD, MPH Dragana Lovre, MD

Summary To assess the effect of a seven-site system-wide LSU HCSD quality improvement project (QIP) To reduce 30-day Heart Failure (HF) readmissions by increasing % of discharged HF patients having post-discharge follow-up outpatient clinic visits to within two weeks of hospital discharge. Informatics and analytical support required for the HF disease management program's HF readmission reduction QIP Hypothesis: timely clinic follow-up after a HF- related inpatient discharge may reduce risk of short-term readmission.

Aims/Methods/Timeline 1: Background Analyses 2: Analysis of Factors Related to Readmission 3: Conduct interim reporting over the course of the QIP. 4: Final Analysis of QIP

Appropriate Lipid Therapy for Heart Failure Patients Lee Arcement, MD, MPH Phillip Paine, MD

Summary To assess the impact of a seven-site system- wide quality improvement project (QIP) To improve appropriate lipid (statin) therapy for eligible patients in the LSU HCSD heart failure (HF) patient population. Informatics and analytical support required for the HF program's lipid control QIP. The QIP project will be directed to improving adherence to the current national guidelines for lipid control in heart failure patients.

Four Possible Problems Some HF patients may not be on statin therapy even though they are eligible for statin therapy and have non-optimal lipid control. Some HF patients on statin therapy still have non- optimal lipid control, due to either inappropriate choice of statin or suboptimal dosing or other clinical factors. Some HF patients on or off statin therapy may be poor candidates for statin therapy due to contraindications or intolerances. Some HF patients on statin therapy may not have an indication for statin therapy

Aims/Methods/Timeline Aim 1: Background Analysis Aim 2: Analysis of factors related to lipid control. Aim 3: Analytical support for identifying methods for categorizing HF patients with regard for eligibility for statin therapy. Aim 4: Conduct interim reporting over course of the QIP project. Aim 5: Conduct final analysis on the effect of the QIP on lipid control levels within the HF patient population.